{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:55Z","timestamp":1786991275435,"version":"build-2736575974"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101057454"],"award-info":[{"award-number":["101057454"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["H2020-EU.3.1.1"],"award-info":[{"award-number":["H2020-EU.3.1.1"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["945151"],"award-info":[{"award-number":["945151"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["H2020-EU.3.1.3"],"award-info":[{"award-number":["H2020-EU.3.1.3"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["202234-30"],"award-info":[{"award-number":["202234-30"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014419","name":"EIT Health","doi-asserted-by":"publisher","award":["CM24\/00143"],"award-info":[{"award-number":["CM24\/00143"]}],"id":[{"id":"10.13039\/100014419","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI21\/00787"],"award-info":[{"award-number":["PI21\/00787"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122160","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:17:23Z","timestamp":1782199043000},"page":"122160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar depression: A systematic review and dose-related network meta-analysis across different age groups"],"prefix":"10.1016","volume":"412","author":[{"given":"Michele","family":"Fornaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-5618.2006.00303.x","article-title":"Inositol augmentation of lithium or valproate for bipolar depression","volume":"8","author":"AE","year":"2006","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jad.2018.11.090","article-title":"Double-blind, placebo-controlled trial of pioglitazone for bipolar depression","volume":"245","author":"Aftab","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1176\/appi.ajp.2016.15040558","article-title":"Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison","volume":"174","author":"Altshuler","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jad.2005.02.018","article-title":"Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression\u2014lack of manic induction","volume":"87","author":"Amsterdam","year":"2005","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jad.2026.122160_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1192\/bjp.bp.115.169375","article-title":"Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate","volume":"208","author":"Amsterdam","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb2025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1399-5618.2011.00971.x","article-title":"Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"14","author":"Anand","year":"2012","journal-title":"Bipolar Disorders"},{"key":"10.1016\/j.jad.2026.122160_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/archpsyc.1994.03950030084009","article-title":"Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors","volume":"51","author":"Artigas","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0706743720970857","article-title":"Comparative efficacy and tolerability of adjunctive pharmacotherapies for acute bipolar depression: a systematic review and network meta-analysis","volume":"66","author":"Bahji","year":"2021","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J. Stat. Softw."},{"issue":"4","key":"10.1016\/j.jad.2026.122160_bb0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00607682","article-title":"Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women","volume":"11","author":"Banki","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/2045125312467348","article-title":"Sleep architecture in ziprasidone-treated bipolar depression: a pilot study","volume":"3","author":"Baskaran","year":"2013","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb2050","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12200","article-title":"A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression","volume":"80","author":"Bauer","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.122160_bb0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: Psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-019-1257-1","article-title":"A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo","volume":"17","author":"Berk","year":"2019","journal-title":"BMC Med."},{"issue":"5","key":"10.1016\/j.jad.2026.122160_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/JCP.0b013e31829a83f5","article-title":"A placebo-controlled trial of acetyl-L-carnitine and \u03b1-lipoic acid in the treatment of bipolar depression","volume":"33","author":"Brennan","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4088\/JCP.v67n0703","article-title":"A 7-week, randomized, double-blind trial of olanzapine\/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression","volume":"67","author":"Brown","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0075","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/acer.12445","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence","volume":"38","author":"Brown","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"12","key":"10.1016\/j.jad.2026.122160_bb0080","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/npp.2014.138","article-title":"A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression","volume":"39","author":"Brown","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.122160_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","article-title":"A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression","volume":"60","author":"Calabrese","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0090","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1399-5618.2007.00500.x","article-title":"Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials","volume":"10","author":"Calabrese","year":"2008","journal-title":"Bipolar Disord."},{"issue":"10","key":"10.1016\/j.jad.2026.122160_bb0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.09m05900gry","article-title":"Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study","volume":"71","author":"Calabrese","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0105","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.4088\/JCP.13m08951","article-title":"Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"75","author":"Calabrese","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2026.122160_bb0110","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.122160_bb0115","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.euroneuro.2014.09.001","article-title":"Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder","volume":"24","author":"Chen","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1399-5618.2000.020107.x","article-title":"Inositol as an add-on treatment for bipolar depression","volume":"2","author":"Chengappa","year":"2000","journal-title":"Bipolar Disord."},{"issue":"4","key":"10.1016\/j.jad.2026.122160_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00004850-198910000-00006","article-title":"A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder","volume":"4","author":"Cohn","year":"1989","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0130","first-page":"20","article-title":"Risperidone side effects","volume":"61","author":"Conley","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.64719\/pb.4065","article-title":"Zonisamide for bipolar depression: a randomized, double blind, placebo-controlled, adjunctive trial","volume":"44","author":"Dauphinais","year":"2011","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2026.122160_bb0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2004.09.009","article-title":"Divalproex in the treatment of bipolar depression: a placebo-controlled study","volume":"85","author":"Davis","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-5618.2009.00728.x","article-title":"A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder","volume":"11","author":"DelBello","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0150","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaac.2017.10.006","article-title":"Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study","volume":"56","author":"DelBello","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaac.2014.12.012","article-title":"Olanzapine\/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial","volume":"54","author":"Detke","year":"2015","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111403","article-title":"Lurasidone versus quetiapine for cognitive impairments in young patients with bipolar depression: a randomized, controlled study","volume":"15","author":"Diao","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.jad.2026.122160_bb0165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0175","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0180","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jad.2018.10.083","article-title":"The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study","volume":"245","author":"Ellegaard","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-2-8","article-title":"Do multiple outcome measures require p-value adjustment?","volume":"2","author":"Feise","year":"2002","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2026.122160_bb0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/cap.2013.0105","article-title":"Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial","volume":"24","author":"Findling","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/NDT.S100846","article-title":"Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review","author":"Fornaro","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2026.122160_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3084859","article-title":"Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews","volume":"2017","author":"Fornaro","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jad.2026.122160_bb0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bdi.12612","article-title":"Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis","volume":"20","author":"Fornaro","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0210","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jad.2020.07.109","article-title":"The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials","volume":"276","author":"Fornaro","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121798","article-title":"Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: a systematic review and dose-related network meta-analysis across different age groups","volume":"407","author":"Fornaro","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2024.01.002","article-title":"Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data","volume":"81","author":"Fountoulakis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.188.1.46","article-title":"Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study","volume":"188","author":"Frangou","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.122160_bb0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0269881106067787","article-title":"Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder","volume":"21","author":"Frangou","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.jad.2026.122160_bb0235","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1176\/appi.ajp.2007.06060981","article-title":"A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression","volume":"164","author":"Frye","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40345-015-0034-0","article-title":"Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments","volume":"3","author":"Frye","year":"2015","journal-title":"Int. J. Bipolar Disord."},{"issue":"15","key":"10.1016\/j.jad.2026.122160_bb0245","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-017-4642-5","article-title":"A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use","volume":"234","author":"Gao","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.122160_bb0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","article-title":"Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials","volume":"194","author":"Geddes","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2215-0366(15)00450-2","article-title":"Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2\u00d7 2 factorial randomised trial","volume":"3","author":"Geddes","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euroneuro.2007.09.002","article-title":"Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients","volume":"18","author":"Geretsegger","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0265","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13136","article-title":"Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a randomized, double-blind, placebo-controlled trial","volume":"82","author":"Ghaemi","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0270","series-title":"Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice","author":"Goldberg","year":"2021"},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0275","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0280","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4088\/JCP.v65n0321","article-title":"A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder","volume":"65","author":"Goodwin","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.jad.2026.122160_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(99)00041-5","article-title":"A double-blind study comparing idazoxan and bupropion in bipolar depressed patients","volume":"56","author":"Grossman","year":"1999","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00645133","article-title":"Disposition of valproic acid in man","volume":"12","author":"Gugler","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2019.10.021","article-title":"Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial","volume":"261","author":"Halaris","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jad.2026.122160_bb0305","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0310","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2026.122160_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jad.2026.122160_bb0320","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0325","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1176\/ajp.148.7.910","article-title":"Tranylcypromine versus imipramine in anergic bipolar depression","volume":"148","author":"Himmelhoch","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.122160_bb0330","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","article-title":"Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0335","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1017\/S1461145703003341","article-title":"Long-term symptomatic status of bipolar I vs. bipolar II disorders","volume":"6","author":"Judd","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/pcn.13137","article-title":"Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression","volume":"74","author":"Kato","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.jad.2026.122160_bb0345","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.biopsych.2006.03.056","article-title":"Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder","volume":"60","author":"Keck","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0350","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bdi.12013","article-title":"Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder","volume":"14","author":"Kemp","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0355","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1176\/appi.focus.20230009","article-title":"The CANMAT and ISBD guidelines for the treatment of bipolar disorder: summary and a 2023 update of evidence","volume":"21","author":"Keramatian","year":"2023","journal-title":"Focus"},{"key":"10.1016\/j.jad.2026.122160_bb0360","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jad.2015.04.012","article-title":"Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder","volume":"181","author":"Ketter","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0365","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1503\/cmaj.101715","article-title":"Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression","volume":"184","author":"Knol","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.jad.2026.122160_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102581","article-title":"Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials","volume":"71","author":"Kong","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/JCP.0000000000000109","article-title":"The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial","volume":"34","author":"Lee","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0380","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00213-016-4215-z","article-title":"Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial","volume":"233","author":"Li","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.122160_bb0385","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2024.25","article-title":"Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis","volume":"67","author":"Li","year":"2024","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0390","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.jad.2026.122160_bb0395","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0400","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jad.2021.09.109","article-title":"A randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate the efficacy and safety of non-racemic amisulpride (SEP-4199) for the treatment of bipolar I depression","volume":"296","author":"Loebel","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0405","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/JCP.0b013e31825ccde5","article-title":"Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?","volume":"32","author":"Lombardo","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0410","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1516-44462011000400011","article-title":"N-acetylcysteine for major depressive episodes in bipolar disorder","volume":"33","author":"Magalh\u00e3es","year":"2011","journal-title":"Brazilian Journal of Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0415","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bdi.13367","article-title":"The diagnosis of bipolar disorder in children and adolescents: past, present and future","volume":"25","author":"Malhi","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0420","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpsychires.2017.07.021","article-title":"Vitamin D supplementation in bipolar depression: a double blind placebo controlled trial","volume":"95","author":"Marsh","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122160_bb0425","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4088\/JCP.08m04942gre","article-title":"A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)","volume":"71","author":"McElroy","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/YIC.0000000000000051","article-title":"Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial","volume":"30","author":"McElroy","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1399-5618.2002.01189.x","article-title":"Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study","volume":"4","author":"McIntyre","year":"2002","journal-title":"Bipolar Disord."},{"issue":"8","key":"10.1016\/j.jad.2026.122160_bb0440","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","article-title":"Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I\/II depression: a randomized clinical trial","volume":"76","author":"McIntyre","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122160_bb0445","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/JCP.0000000000000938","article-title":"Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: a double-blind controlled clinical trial","volume":"38","author":"Mehrpooya","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0450","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40345-023-00300-z","article-title":"Characteristics of rapid cycling in 1261 bipolar disorder patients","volume":"11","author":"Miola","year":"2023","journal-title":"International Journal of Bipolar Disorders"},{"key":"10.1016\/j.jad.2026.122160_bb0455","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0460","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00213-018-4977-6","article-title":"Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression","volume":"235","author":"Murasaki","year":"2018","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jad.2026.122160_bb0465","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1176\/appi.ajp.158.6.906","article-title":"Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression","volume":"158","author":"Nemeroff","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0470","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0475","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.ajp.163.2.210","article-title":"Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone","volume":"163","author":"Nierenberg","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2026.122160_bb0485","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/13696998.2022.2030147","article-title":"The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis","volume":"25","author":"Niu","year":"2022","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.jad.2026.122160_bb0490","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-0447.2007.00993.x","article-title":"Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study","volume":"115","author":"Nolen","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2026.122160_bb0495","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2215-0366(24)00006-3","article-title":"Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis","volume":"11","author":"Oliva","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0505","article-title":"Bipolar disorders: an update on critical aspects","volume":"48","author":"Oliva","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.jad.2026.122160_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103413","article-title":"Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials","volume":"87","author":"Oliva","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2026.122160_bb0510","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0515","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000693","article-title":"A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression","volume":"37","author":"Park","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0520","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-5618.2010.00850.x","article-title":"Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder","volume":"12","author":"Pavuluri","year":"2010","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2222","article-title":"Lamotrigine for acute bipolar depression: an exploratory item-level analysis","volume":"11","author":"Peters","year":"2021","journal-title":"Brain Behav."},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0530","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1192\/bjp.bp.105.013045","article-title":"Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline","volume":"189","author":"Post","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0535","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hup.1096","article-title":"Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study","volume":"25","author":"Quante","year":"2010","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jad.2026.122160_bb0540","first-page":"35","article-title":"Sedation intensity during dose escalation of quetiapine XR or IR in bipolar depression: a multicenter, double-blind, randomized, phase IV study","author":"Riesenberg","year":"2011","journal-title":"International Journal Of Psychiatry In Clinical Practice"},{"issue":"11","key":"10.1016\/j.jad.2026.122160_bb0545","first-page":"2202","article-title":"Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study","volume":"34","author":"Riesenberg","year":"2011","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2026.122160_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2026.122160_bb0555","series-title":"WebPlotDigitizer","author":"Rohatgi","year":"2017"},{"key":"10.1016\/j.jad.2026.122160_bb0560","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"issue":"17","key":"10.1016\/j.jad.2026.122160_bb0565","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa064135","article-title":"Effectiveness of adjunctive antidepressant treatment for bipolar depression","volume":"356","author":"Sachs","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0570","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-017-0073-7","article-title":"Treatment of bipolar depression with minocycline and\/or aspirin: an adaptive, 2\u00d7 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial","volume":"8","author":"Savitz","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jad.2026.122160_bb0575","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jad.2006.05.023","article-title":"Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression","volume":"96","author":"Schaffer","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0580","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/acps.13692","article-title":"Phenotypic clustering of bipolar disorder supports stratification by lithium responsiveness over diagnostic subtypes","volume":"150","author":"Scott","year":"2024","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0585","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WNF.0000000000000011","article-title":"Bupropion as an add-on therapy in depressed bipolar disorder type I patients with comorbid cocaine dependence","volume":"37","author":"Sepede","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0590","article-title":"Dose-response meta-analysis: application and practice using the R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiology and Health"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0595","doi-asserted-by":"crossref","DOI":"10.1034\/j.1600-0447.2001.00240.x","article-title":"Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial","volume":"104","author":"Silverstone","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2026.122160_bb0600","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1089\/cap.2020.0018","article-title":"Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial","volume":"30","author":"Singh","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0605","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2174\/1570159X20666220927112625","article-title":"Sleep disturbance, irritability, and response to lurasidone treatment in children and adolescents with bipolar depression","volume":"21","author":"Singh","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0610","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(25)01140-7","article-title":"Bipolar disorder","volume":"406","author":"Singh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2026.122160_bb0615","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0893-133X(98)00129-8","article-title":"Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression: a placebo-controlled trial","volume":"20","author":"Smeraldi","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.122160_bb0620","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S1092852916000869","article-title":"Mixed features in bipolar disorder","volume":"22","author":"Sol\u00e9","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2026.122160_bb0625","series-title":"State-Trait Anxiety Inventory for Adults","author":"Spielberger","year":"1983"},{"key":"10.1016\/j.jad.2026.122160_bb0630","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1038\/s41598-021-84836-z","article-title":"A network meta-analysis of the dose\u2013response effects of lurasidone on acute schizophrenia","volume":"11","author":"Srisurapanont","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0635","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00427274","article-title":"A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder","volume":"81","author":"Standish-Barry","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.122160_bb0640","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jad.2026.122160_bb0645","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.56.5.407","article-title":"Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial","volume":"56","author":"Stoll","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0650","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jad.2008.02.004","article-title":"A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression","volume":"111","author":"Suppes","year":"2008","journal-title":"J. Affect. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jad.2026.122160_bb0655","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0660","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2016.03.012","article-title":"Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts","volume":"78","author":"Suppes","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122160_bb0665","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bdi.13310","article-title":"Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized placebo-controlled clinical trial","volume":"25","author":"Suppes","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0670","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpsychires.2015.06.015","article-title":"Antidepressant dose and treatment response in bipolar depression: reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data","volume":"68","author":"Tada","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122160_bb0675","series-title":"R: A Language and Environment for Statistical Computing","author":"Team, R.C","year":"2023"},{"issue":"6","key":"10.1016\/j.jad.2026.122160_bb2675","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0680","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies","volume":"28","author":"Thase","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0685","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122160_bb0690","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","article-title":"Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression","volume":"201","author":"Tohen","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0695","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.focus.23021025","article-title":"Prevention of suicidal behavior in bipolar disorder","volume":"21","author":"Tondo","year":"2023","journal-title":"Focus"},{"issue":"2","key":"10.1016\/j.jad.2026.122160_bb0700","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00702-017-1817-5","article-title":"A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression","volume":"125","author":"Toniolo","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jad.2026.122160_bb0705","series-title":"Exploratory Data Analysis","author":"Tukey","year":"1977"},{"issue":"04\/05","key":"10.1016\/j.jad.2026.122160_bb0710","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0034-1383654","article-title":"Influence of levothyroxine in augmentation therapy for bipolar depression on central serotonergic function","volume":"47","author":"Uhl","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0715","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4088\/JCP.08m04152","article-title":"Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial","volume":"70","author":"van der Loos","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0720","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.jad.2026.122160_bb0725","doi-asserted-by":"crossref","unstructured":"Wang, M., Tong, J.-h., Huang, D.-s., Zhu, G., Liang, G.-m., Du, H., 2014. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. Psychopharmacology 231, 2811\u20132818.","DOI":"10.1007\/s00213-014-3453-1"},{"key":"10.1016\/j.jad.2026.122160_bb0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2007.09.012","article-title":"Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence","volume":"108","author":"Weisler","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0735","doi-asserted-by":"crossref","first-page":"31","DOI":"10.64719\/pb.4449","article-title":"A randomized, double-blind, controlled clinical trial of omega-3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5\u201312","volume":"52","author":"Wozniak","year":"2022","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.jad.2026.122160_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2026.112818","article-title":"Treatment of bipolar depression: results from a comprehensive network meta-analysis and updated systematic review","volume":"108","author":"Yalin","year":"2026","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0745","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1192\/bjp.bp.114.147587","article-title":"Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial","volume":"208","author":"Yatham","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122160_bb0750","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122160_bb0755","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","author":"Yatham","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122160_bb0760","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2026.122160_bb0765","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/npp.2009.2","article-title":"Decreased glutamate\/glutamine levels may mediate cytidine\u2019s efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study","volume":"34","author":"Yoon","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0770","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1176\/ajp.157.1.124","article-title":"Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression","volume":"157","author":"Young","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122160_bb0775","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","article-title":"Pramipexole for bipolar II depression: a placebo-controlled proof of concept study","volume":"56","author":"Zarate","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.122160_bb0780","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122160_bb0785","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/da.22340","article-title":"Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Zeinoddini","year":"2015","journal-title":"Depress. Anxiety"},{"issue":"4","key":"10.1016\/j.jad.2026.122160_bb0790","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S2215-0366(25)00338-4","article-title":"Dose-dependent pharmacological mechanisms within the neuroscience-based nomenclature: a new concept to facilitate neuroscience-based prescribing","volume":"13","author":"Zemach","year":"2026","journal-title":"Lancet Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.jad.2026.122160_bb0795","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jpsychires.2005.06.002","article-title":"Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study","volume":"41","author":"Zhang","year":"2007","journal-title":"J. Psychiatr. Res."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726010128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726010128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:04:56Z","timestamp":1784577896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726010128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":162,"alternative-id":["S0165032726010128"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122160","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar depression: A systematic review and dose-related network meta-analysis across different age groups","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122160"}}